Replies to post #41076 on OncoSec Medical Inc (ONCSQ)

[lasers]

Would you copy and paste what he is saying.

[hschlauch]

One significant, yet overlooked point regarding the phase 2 combination trial for predicted nonresponders...

The selected patients had VERY low partially exhausted T cell percentages. In other words, they were selecting the worst of the worst immunologically speaking. None of the patients had more than 22% PD-1-positive CD8 T cells. The PISCES trial will enroll actual progressing patients to anti-PD-1 therapy who have higher percentages of the partially exhausted phenotype; this bodes very well for Oncosec and Merck. Not all anti-PD-1 nonresponders have such low levels of inflamed tumors. Again, the trial selected the worst of the worst. In fact, some of these patients didn't have any detectable CD8 T cells with the exhausted phenotype.

The PISCES trial will do well in my opinion, based on the simple fact that there will be more patients with relatively higher partially exhausted phenotype at baseline.

I still cannot get over those CR numbers! Nearly every single responder to the combo became a complete response over time, and none of those patients are progressing.